Pharmaceutically active compounds
US6677335B1 · kind B1 · utility
4Cited by
14References
12Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 6, 2000 |
| Grant date | Jan 13, 2004 |
| Priority date | — |
| Expiry date | Oct 6, 2020 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D487/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Compounds of the formula (I): wherein R1, R2, R4 and R13 are as defined or a pharmaceutically or veterinarily acceptable salt or polymorph thereof, or a pharmaceutically or veterinarily acceptable solvate or pro-drug thereof: are potent and selective inhibitors of type 5 cyclic guanosine 3′,5′-monophosphate phosphodiesterase (cGMP PDE5) and have utility in the treatment of, inter alia, male erectile dysfunction (MED) and female sexual dysfunction (FSD).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.